Tangram Therapeutics
Tangram Therapeutics combines computational drug discovery with biology to develop RNAi medicines, led by TGM-312 for MASH liver disease.
tangramtx.com ↗Why it's here
Announced in March 2026 that the first participant was dosed in the Phase 1/2 RESTORE-MASH trial of TGM-312, and in September 2026 that the trial had moved into MASH patient cohorts.
source: tangramtx.com- Focus
- RNAi therapeutics
- Latest round
- Subscription by M&G and Richard Griffiths, £28.9M, Jul 2024
- London office
- Floor 4, 4 Kingdom Street, Paddington Central, London, Westminster W2 6BDsource: tangramtx.com
- London presence
- HQsource: tangramtx.com
- Area
- Paddington
- Nearest station
- Paddington, 451 m
- Visas
- Licensed visa sponsor, listed as Tangram Therapeutics Plcsource: gov.uk
- Elsewhere
- LinkedIn ↗
Verified 8 Oct 2026. How we verify · Suggest a fix
For Tangram Therapeutics
Work here? Show you're on the map. Add the badge to your site or README, or share the listing.
<a href="https://londonmempool.co.uk/c/tangram-therapeutics"><img src="https://londonmempool.co.uk/badge/tangram-therapeutics.svg" alt="Tangram Therapeutics is listed on London Mempool" width="357" height="28"></a>
Add ?theme=light to the image URL for light backgrounds.
Same building
2 more companies on the map list this office address.